The reform package that circulated in December 2025 finally puts an explicit “breakthrough” or accelerated pathway on the table for certain high‑need devices. To be fair, this isn’t a magic shortcut — it’s a rejig of incentives and obligations that will matter most to small and mid‑size teams trying to get novel devices to patients without drowning in cyclic additional-data requests.
I’ve been the RA lead on Class IIa/IIb dossiers through multiple MDR cycles. The devil is, as ever, in the details: how notified bodies interpret “safety first” versus “timely access”, how manufacturers document conditional approvals, and how PMCF and PMS are enforced afterwards. Below I translate the practical consequences of the proposals and give a short checklist for teams with an audit or CE submission due in the next 12 months.
What the “breakthrough” pathway is designed to do (practical reading)
In plain terms, the proposals aim to:
- Create an accelerated assessment route for devices that address an unmet clinical need or offer a substantial improvement over existing options.
- Allow a more modular evidence strategy: earlier market access based on a narrower pre‑market package, with stricter and tightly monitored post‑market requirements.
- Tighten the link between conditional authorisation and active PMCF/PMS obligations, with clearer milestones and reporting triggers.
To be fair, regulators are trying to balance two things: patient access to innovation and the MDR’s higher baseline for clinical evidence. In practice this means more emphasis on real‑world evidence and enforceable PMCF rather than a lower bar for initial clinical data.
Three concrete changes that will matter to RA/QA teams
-
Evidence becomes staged, not absent
- You can expect notified bodies to accept a smaller clinical package pre‑market if there is a robust, time‑bound PMCF plan with clear triggers and data collection methods.
- That shifts workload from pre‑market dossier assembly to post‑market systems design: PMS, PMCF, registries, and data pipelines must be ready on Day 1.
-
Conditional approvals mean harder surveillance
- Conditional or accelerated CE will come with contractual or regulatory milestones — expect tighter scrutiny at surveillance audits and more frequent PSUR/SSCP updates.
- In practice this means your CAPA and change‑control processes must be able to handle near‑real‑time evidence gaps and corrective actions.
-
Notified bodies get clearer remit — but interpretations will still vary
- The proposals attempt to clarify criteria for accelerated routes and the role of expert panels. That should reduce arbitrary equivalence rejections, granted, but local interpretation and resource constraints at notified bodies will still determine speed.
- Early, structured engagement with your chosen NB will remain essential.
What to do now — a practical checklist for SMEs
You cannot wait until the final text to prepare. Here’s what I’d prioritise this quarter:
- Strengthen your PMCF and PMS design
- Map real‑world data sources (clinics, registries, device telemetry).
- Make PMCF protocols prescriptive: objectives, endpoints, timelines, interim analyses.
- Put traceability where it matters
- Link clinical objectives to risk controls and post‑market actions in your Technical File (Annex II material).
- Use connected workflow tools so change control, CAPA, and risk assessments update the TF automatically.
- Rehearse conditional milestones
- Draft PSUR/SSCP update templates with triggers mapped to PMCF milestones.
- Ensure contractual readiness for enhanced surveillance (supplier agreements, clinical sites).
- Talk to your notified body early
- Present a staged evidence plan and ask for written expectations about PMCF milestones and audit frequency.
- Invest in real‑time CAPA capability
- If you haven’t already, introduce automated CAPAs or AI‑assisted prioritisation to handle potentially higher rates of PMS signals. The emphasis must be on controlled assistance and reviewability — regulators will want to know who signed off on what.
Why this still won’t be easy
A faster pathway on paper does not mean fewer obligations. If anything, the net burden shifts:
- Pre‑market work gets narrower but PMCF becomes more operationally demanding.
- Notified bodies will need to police conditional approvals. If NB capacity isn’t increased in parallel, you’ll see delays at the review and surveillance stages.
- EUDAMED and UDI infrastructure alignment remains critical. You may need to submit interim data earlier and more often.
From experience, these operational gaps are where small teams fail: strong technical files but weak PMS pipelines. The reform proposals recognise that, but they don’t buy you the time to build those systems after you’re on the market.
Quick note on tooling — what features actually help
If you’re thinking about tooling, focus on functionality that supports a staged evidence model:
- Traceability across TF, risk assessments, PMCF and CAPA (connected workflow).
- Change impact mapping visible in one place so you can show linkage between a PMCF signal, a CAPA and a TF update.
- Automated CAPAs and AI‑assisted prioritisation to triage incoming PMS data — always with audit trails and human review baked in.
- Templates for PMCF protocols and PSUR cycles mapped to milestones.
Those are not marketing talking points; they are the workflows that get inspected.
Final thought
The December 2025 proposals are a meaningful step towards balancing innovation and safety. For small teams, the opportunity is clearer pathways to patients — provided you can operationalise a high‑quality PMCF/PMS regime and maintain tight traceability.
Which part of your QMS would you prioritise to be ready for a conditional/accelerated pathway: PMCF design, real‑world data pipelines, or CAPA automation?
